VEGFA and diabetic retinopathy: cAMP has potential therapeutic value in diabetic retinopathy by maintaining the retinal vascular barrier (which regulates the tight junction protein Zonula Occludens-1), inhibiting the release of vascular endothelial growth factor (VEGF), and suppressing microglial activation [145].